This first biannual report from the Cochrane Haematologiocal Malignancies Group (CHMG) highlights recently published systematic reviews as well as a selection of recently published and ongoing randomized controlled trials from the CHMG Trials Register (http://www.update-software.com/cochrane/). This register is being developed and maintained by the CHMG and currently contains references to approximately 3600 reports of randomized controlled trials that cover the scope of the group, including Hodgkin lymphoma, nonHodgkin lymphoma, acute and chronic leukemias, aplastic anemia, and myelodysplastic syndromes.
Implications for practice. Prophylactic G-CSF/GM-CSF for all lymphoma patients undergoing standard-dose chemotherapy cannot be recommended based on the data reviewed. However, prophylaxis may be used in patients at high risk of neutropenic complications (i.e., expected incidence ≥40%).
CHMG Protocols
Baldo P, Bearz A, Cannizzaro R, Canzonieri V, Dal Maso L, Di Lauro V, et al. Interferonalpha for follicular lymphoma (Protocol for a Cochrane Review). In: The Cochrane Library. 
PUBLISHED TRIALS Hodgkin Lymphoma
Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Lippincott; 2001 . p. 2339 . At 5 years, both overall and event-free survival of patients randomly assigned to receive two cycles of cyclophosphamide, vincristine, procarbazine, prednisone and doxorubicin, bleomycin, vinblastine, dacarbazine (COPP/ABVD) plus involved field irradiation were similar to those in patients assigned to receive two cycles of COPP/ABVD plus extended field irradiation. The incidence of severe toxicities was clinically and statistically significantly lower in patients receiving involved field irradiation.
Implications for practice. Two cycles of COPP/ABVD plus involved field irradiation is as effective as two cycles of COPP/ABVD plus extended field irradiation but less toxic in patients with early-stage unfavorable Hodgkin lymphoma and should therefore be used in these patients. . NNT/NNH = number needed to treat and number needed to harm, respectively. The numbers needed to treat or harm are translations of the absolute risk reduction (ARR) into clinical useful terms. They are calculated as the reciprocal of the ARR. The NNT is the average number of patients that needs to be treated with a particular therapy to prevent one additional bad outcome. The NNH is the average number of patients a clinician needs to treat for one additional patient to be harmed. Clinical background. Randomized trials comparing a watch-and-wait approach with immediate treatment in patients with advanced low-grade lymphoma are limited by their small numbers of patients and short follow-up.
Most interesting features.
Contribution. In this multicenter trial, asymptomatic patients with stage III/IV low-grade lymphoma (mostly grade I-II follicular lymphoma) were followed for a median of 16 years. There was no difference, at 5, 10, and 15 years, in the overall survival of patients randomly assigned to watch-and-wait compared with the group of patients treated with chlorambucil (given continuously until disease progression or complete remission). At 10 years, the chance of not needing chemotherapy and of not dying of lymphoma was 19% (95% CI = 13% to 27%) in the watch-and-wait group.
Implications for practice.
A watch-and-wait approach in asymptomatic, advanced stage low-grade non-Hodgkin lymphoma patients is adequate.
Most interesting features.
Very long follow-up with very few losses to follow-up.
Key study features are as follows. Clinical background. Randomized trials in patients with aggressive non-Hodgkin lymphoma of more aggressive second-and third-generation regimens have failed to show any survival benefits compared with the cyclophosphamide, doxorubicin, vincristin, prednisone (CHOP) regimen.
Contribution. This large multicenter trial randomly assigned patients (aged 61-69 years) with poor-prognosis aggressive non-Hodgkin lymphoma to either eight cycles of CHOP or to ACVBP-a more aggressive regimen with additional central nervous system prophylaxis (induction: four cycles of doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone, and intrathecal methotrexate plus G-CSF [every 3 weeks]; sequential consolidation: two courses of methotrexate plus leucoverin rescue, four courses of etoposide, ifosfamide, two courses of cytosine-arabinoside [every course administered every other week]). Although results in participants randomly assigned to CHOP or to ACVBP were not different with regard to complete remission rates, event-free survival and overall survival in the ACVBP group was clinically and statistically significantly longer. However, the incidence of grade III/IV toxicities and the rate of treatment-related deaths were higher for patients treated with the more aggressive regimen.
Implications for practice. The survival benefit of ACVBP may be offset by the high incidence of severe side effects, and therefore this regimen cannot yet be generally recommended. Clinical background. Multiple myeloma is an incurable malignancy, even with autologous stem-cell transplantation. Therefore, treatment options that prolong survival are needed.
Contribution. This randomized trial found that event-free survival and overall survival can be prolonged in patients younger than 60 years of age with previously untreated multiple myeloma treated with double autologous transplantation (two successive transplantations; in this study the transplantations were a median of 2.5 months apart) as compared with single transplantation. Treatment-related deaths and hematopoietic reconstitution were similar in both groups. Patients who relapsed after transplantation had the same probability of surviving 2 years after relapse, regardless of whether they received single or double transplantation.
Implications for practice. The possibility of a second autologous transplantation should be considered in patients who do not have a very good partial response or better after first transplantation but who tolerated the procedure well.
Relatively long follow-up and large sample size. Clinical background. High rates of relapse are common among patients with acute myeloid leukemia due to residual cells that escape cytotoxic chemotherapy. Administration of G-CSF during induction remission therapy may be beneficial, but clinical trials have been limited by their small numbers of patients.
Key study features are as follows.
Contribution. Disease-free survival was prolonged (both clinically and statistically significantly) in patients with acute myelogenous leukemia randomly assigned to G-CSF during induction remission therapy compared with those assigned to no G-CSF. However, overall survival and event-free survival were similar in both arms. The incidence of grade III/IV infections was also not different.
Implications for practice.
Although improved disease-free survival may indicate sensitization of leukemic cells by G-CSF, the general application of G-CSF during induction remission therapy cannot be recommended based on these data.
Most interesting feature. Relatively large sample size.
Key study features are as follows.
Sample size calculation Unclear (power analysis); assumptions not justified 1 Randomization Generation of allocation sequences: not specified Allocation: not specified Blinding Open-label Setting
Various centers in The Netherlands, Belgium, Germany, Switzerland Number of patients assessed for eligibility: not specified 655 participants randomized Follow-up Planned: not specified Median Clinical background. Prophylactic intravenous immunoglobulins are being widely used in patients undergoing allogeneic stem-cell transplantation despite a lack of evidence about effectiveness.
Contribution. This randomized, double-blind, placebo-controlled trial recruited 200 patients-most of them with hematological malignancies-who underwent allogeneic stemcell transplantation from human leukocyte antigen (HLA)-identical sibling donors. At 6 months, the incidence of infections was not different between patients randomized to placebo (5% dextrose solution) or to intravenous immunoglobulins (given weekly from day 7 to day 100). There were also no differences in treatment-related mortality at 6 months and overall survival at 2 years.
Implications for practice. Administration of prophylactic intravenous immunoglobulins is not superior to dextrose solution in patients undergoing allogeneic stem-cell transplantation from HLA-identical siblings and should therefore not be used in these patients.
Most interesting feature. Placebo-controlled trial. Key study features are as follows. This report of a randomized, controlled, open-label trial describes quality-of-life outcomes in 247 patients with early-stage Hodgkin lymphoma treated with either subtotal lymphoid irradiation or combined-modality therapy. Combined-modality therapy decreased short-term quality-of-life (6 months after treatment start), but quality of life after 1 year was similar in both treatment arms.
Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med 2003; 349:1423-32. This report of a previously published randomized, controlled trial (IRIS) shows the effect of imatinib mesylate on the molecular response rate in 1106 patients with chronic myeloid leukemia in chronic phase. A significantly (clinically and statistically) greater proportion of patients treated with imatinib had a reduction of BCR-ABL transcript levels (≤0.001 multiplied by baseline value) after 12 months compared with patients treated with interferon alfa plus cytarabine.
Schouten HC, Qian W, Kvaloy S, Porcellini A. Hagberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21:3918-27. This trial examined the effectiveness of high-dose chemotherapy followed by autologous stem-cell transplantation versus standard-dose chemotherapy in 89 patients with relapsed follicular non-Hodgkin lymphoma. It remains unclear if a change in the randomization ratio during the trial introduced bias (19 of the 89 patients were randomly assigned only between unpurged and purged stem-cell transplantation). Nevertheless, this trial showed that patients may benefit from high-dose chemotherapy in terms of progression-free survival and overall survival.
Solary E, Drenou B, Campos L, de Cremoux P, Mugneret F, Moreau P, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003; 102:1202-10. This randomized controlled trial examined the effect of quinine in combination with induction chemotherapy versus induction chemotherapy alone on survival in adult de novo acute myeloid leukemia. Quinine did not improve either complete response rate or overall survival in these patients.
ONGOING TRIALS Chronic Lymphocytic Leukemia
Phase III randomized study of chlorambucil alone versus fludarabine with or without cyclophosphamide in patients with newly diagnosed chronic lymphocytic leukemia. Catovsky D (Royal Marsden NHS Trust, London, U.K.) [available at: http://www.clinicaltrials.gov].
Question. In patients with previously untreated chronic lymphocytic leukemia, is fludarabine used alone or in combination with cyclophosphamide superior to chlorambucil (in terms of overall survival)?
